-

Medable to Present at 42nd Annual J.P. Morgan Healthcare Conference

original (Graphic: Business Wire)

(Graphic: Business Wire)

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology provider for modern clinical trials, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 10, 2024, at 7:30 AM Pacific Time (10:30 AM Eastern Time).

About Medable

Medable, a Software as a Service (SaaS) cloud platform, is revolutionizing clinical drug development. Our innovative AI-driven technology is transforming clinical trial evidence data collection, analysis, and application, resulting in increased speed and efficiency to bring life-saving therapies to patients faster. We are accelerating the generation of critical evidence by digitizing and connecting with patients at consumer scale. The flexibility of our technology has powered 300+ clinical trials, across 70+ countries, in 115+ languages, with over 1M patients having utilized our platform, ensuring broader, more diverse patient engagement. Medable is trusted by 14 of the top 20 pharmaceutical companies and 9 of the top 10 CROs. To date, we have secured $500M+ in funding from top-tier investors, including Blackstone, Sapphire, PPD/ThermoFisher, and GSR Ventures.

Contacts

Nora Volger, SVP Marketing, Medable
Nora.Volger@medable.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

Industry:

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI
Release Summary
Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference.
Release Versions
English
Hashtags
#jpm2024

Contacts

Nora Volger, SVP Marketing, Medable
Nora.Volger@medable.com / media@medable.com

Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com

More News From Medable Inc.

MRCT Center and Medable Launch New Resources for Investigator Oversight in Decentralized Clinical Trials

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of agentic clinical development technology, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) today announced new resources for sponsors and investigators. The tools will be available beginning September 23, 2026. The resources and practical tools help sponsors and investigators determine which trial activities can appropriately take place closer to participants and establi...

Medable and ICON Exceed Patient eConsent Adoption Goals for Women’s Health Study on Menopause

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced the impact of its Total Consent solution in a U.S women’s health study on menopause managed by ICON plc. Beating expectations, more than 85% of trial participants, or 1,044 out of 1,222, consented using Medable’s enhanced eConsent technology. And, 18 sites achieved 100% eConsent adoption among participants, while the top-enrolling site achieved 91% adoption. With...

New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience d...
Back to Newsroom